Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial.

MLA

González Cao, María, et al. “Biochemotherapy with Low Doses of Subcutaneous Interleukin-2 in Patients with Melanoma: Results of a Phase II Trial.” Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 7, no. 6, July 2005, pp. 250–54. EBSCOhost, https://doi.org/10.1007/BF02710171.

APA

González Cao, M., Puig, S., Malvehy, J., Herrero, J. E., Martí, R. M., Conill, C., Sánchez, M., Mellado, B., Gascón, P., & Castel, T. (2005). Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 7(6), 250–254. https://doi.org/10.1007/BF02710171

Chicago

González Cao, María, Susana Puig, Josep Malvehy, Josep Eugeni Herrero, Rosa María Martí, Carlos Conill, Marcelo Sánchez, Begoña Mellado, Pere Gascón, and Teresa Castel. 2005. “Biochemotherapy with Low Doses of Subcutaneous Interleukin-2 in Patients with Melanoma: Results of a Phase II Trial.” Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 7 (6): 250–54. doi:10.1007/BF02710171.